xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"

SCHEDULES

Regulation 3A(2)

[F1SCHEDULE 2BN.I.Criteria to be [F2an eligible] arrival

Textual Amendments

1.  P is [F3an “eligible”] arrival if P complies with any of paragraphs 2 to 6.N.I.

Textual Amendments

2.  P complies with this paragraph if P—N.I.

(a)has completed a course of doses of an authorised vaccine with the final dose having been received before the start of the period beginning with the 14th day before the date of P’s arrival in Northern Ireland,

F4(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F5(c). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(d)is able to provide proof, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, of meeting the requirement in sub-paragraph (a) through—

(i)the NHS COVID pass, certification issued by the Department of Health, or equivalent from NHS Scotland or NHS Wales,

(ii)the EU Digital COVID Certificate, F6...

[F7(iia)a North American Certificate;

(iib)a certificate of COVID-19 records issued by an approved third country or territory;]

(iii)the Centres for Disease Control and Prevention vaccination card, F8...

[F9(iv)a vaccine certificate [F10, and]]

F11(e). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(f)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria F12....

Textual Amendments

3.  P complies with this paragraph if P [F13is ordinarily resident in Northern Ireland and]—N.I.

(a)has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004,

(b)is able to provide proof of such participation, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, and

(c)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria F14....

Textual Amendments

4.  P complies with this paragraph if P—N.I.

(a)has participated, or is participating, in a clinical trial regulated in the United States of America by the Food and Drugs Administration of a vaccine for vaccination against coronavirus,

(b)is able, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, to provide proof of such participation through the Centres for Disease Control and Prevention vaccination card, [F15and]

(c)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria F16... F17...

F18(d). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

[F194A.—(1) P meets the conditions of this regulation if P—N.I.

(a)has participated. or is participating in, phase 2 (therapeutic exploratory studies) or phase 3 (clinical efficacy and safety studies) of a clinical trial of a vaccine for vaccination against coronavirus which is regulated by—

(i)the European Medicines Agency, or

(ii)a regulatory authority (other than such an authority in the United Kingdom or the United States of America) which is designated as a Stringent Regulatory Authority by the World Health Organisation;

(b)if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland is able to provide proof of such participation through a participation document, and

(c)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria.

(2) For the purposes of this regulation “participation document” means a document in English, French or Spanish issued by a relevant person which confirms—

(a)P’s full name;

(b)P’s date of birth;

(c)the name and manufacturer of the vaccine;

(d)the country or territory in which the clinical trial is taking, or took, place;

(e)the regulatory authority responsible for the regulation of the clinical trial;

(f)the phase of the clinical trial in which P is participating or participated.

(3) For the purposes of paragraph (2) “relevant person” means—

(a)the competent health authority of the country or territory in which the relevant clinical trial is being, or was, carried out, or

(b)the person who is conducting, or conducted, the relevant clinical trial.]

Textual Amendments

5.  P complies with this paragraph if P is—N.I.

(a)under the age of 18 years upon arrival in Northern Ireland F20...

F21(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

6.  P complies with this paragraph if P is F22...—N.I.

(a)a person who—

(i)has completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas, with the final dose having been received before the start of the period beginning with the 14th day before the date of their arrival in Northern Ireland,

(ii)is able to provide proof, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, of meeting the requirements in paragraph (i), and

(iii)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria F23... F24...

F25(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

[F267.—(1) For the purposes of paragraph 2—N.I.

(a)P has completed a course of doses if P has received the complete course of doses specified—

(i)in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or

(ii)in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 for the authorised vaccine;

[F27(aa)if P has received at least 2 doses of any of the vaccines referred to in sub-paragraph (c) of the definition of “authorised vaccine” in paragraph 10, P is deemed to have completed a course of doses of an authorised vaccine.]

(b)if P has received a dose of one authorised vaccine and a dose of a different authorised vaccine, P is deemed to have completed a course of doses of an authorised vaccine.]

Textual Amendments

F287A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .N.I.

Textual Amendments

[F297B.—(1) For the purposes of paragraph 6—N.I.

(a)P has completed a course of doses of a vaccine if P has received the complete course of doses of the vaccine as specified in the manufacturer’s guidance for that vaccine;

[F30(aa)if P has received a dose of an authorised vaccine in a relevant country, and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have completed a course of doses of an authorised vaccine;]

(b)where P has received a dose of an authorised vaccine F31... and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas;

(c)where P has received a dose of one vaccine under the United Kingdom vaccine roll-out overseas, and a dose of a different vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas.]

[F32(2) Where P is a person described in paragraph (1)(b), the proof which P provides for the purposes of paragraph 6(1)(a)(ii) must include proof of having received the dose of an authorised vaccine through—

(a)the NHS COVID pass, certification issued by the Department of Health, or equivalent from NHS Scotland or NHS Wales;

(b)the EU Digital COVID certificate;

[F33(ba)a North American Certificate;

(bb)a certificate of COVID-19 records issued by an approved third country or territory;]

(c)the Center for Disease Control and Prevention vaccination card; or

(d)a vaccine certificate.]

Textual Amendments

F348.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .N.I.

Textual Amendments

F358A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .N.I.

Textual Amendments

9.  For the purposes of this Schedule a child is to be treated as making a declaration on a Passenger Locator Form, and providing any proof required, if that declaration is made, and the proof provided, by a person who is travelling with and has responsibility for that child.N.I.

10.  In this Schedule—N.I.

“authorised vaccine” means a medicinal product for vaccination against coronavirus [F36which—]

(a)

in relation to doses received in the United Kingdom [F37, is authorised]—

(i)

for supply in the United Kingdom in accordance with a marketing authorisation, or

(ii)

by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012;

(b)

[F38in relation to doses received in a relevant country listed in the table in paragraph 11, is authorised for supply in that relevant country following evaluation by the regulator for that relevant country,

(c)

in relation to doses received [F39any other country or territory (including a relevant country listed in paragraph 12)], [F40—

(i)

would be authorised as provided for in sub-paragraph (a)(i) or (ii) if the doses were received in the United Kingdom, or

(ii)

are listed in lines 10, 11 or 13 of the guidance document “Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process” published by the World Health Organisation on 11th November 2021F41, and authorised or certified in a regulated country listed in paragraph 12,]]

“clinical trial” has the meaning given in regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2004,

[F42“the COVID-19 vaccination eligibility criteria” means the conditions in any of paragraphs 2 to 6,]

“Crown servant” has the meaning given in section 12(1)(a) to (e) of the Official Secrets Act 1989,

“government contractor” has the meaning given in section 12(2) of the Official Secrets Act 1989,

“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012,

“marketing authorisation”—

(a)

in relation to a vaccine authorised for supply in the United Kingdom or in a member State, has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012,

(b)

in relation to a vaccine authorised for supply in a relevant country [F43listed in the table in paragraph 11] other than a member State, means a marketing authorisation granted by [F44the regulator for that relevant country],

“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012,

“NHS COVID pass” means the COVID-19 records [F45available] on the NHS smartphone app developed and operated by the Secretary of State, through the website at NHS.uk or [F46in] a COVID-19 post vaccination letter obtained from the NHS,

“NHS” means the health service continued under section 1(1) of the National Health Service Act 2006,

“NHS Scotland” means the health service continued under section 1(1) of the National Health Service (Scotland) Act 1978,

“NHS Wales” means the health service continued under section 1(1) of the National Health Service (Wales) Act 2006,

[F47”North American Certificate” means, in relation to a State, District or Province listed in the table in paragraph 10B, the certificate identified in the corresponding row of the second column of that table;]

[F48“regulator”, in relation to a relevant country listed in the table in paragraph 11, means the regulator identified in the corresponding row of the second column of the table in that paragraph, and a reference to a regulator in that table is a reference to the regulatory authority of that name designated as a Stringent Regulatory Authority by the World Health Organization pursuant to the operation of the COVAX Facility,]

“relevant country” means a country listed in the first column of the table in paragraph 11 [F49or a country or territory listed in paragraph 12],

F50...

“relevant service” means a commercial transport service carrying passengers to Northern Ireland from outside the common travel area,

“United Kingdom vaccine roll-out overseas” means the administration of vaccination against coronavirus to—

(a)

Crown servants, government contractors or other personnel posted or based overseas and their dependants under the scheme known as the Foreign, Commonwealth and Development Office staff COVID-19 vaccination programme;[F51or]

(b)

F52...

(c)

military or civilian personnel, government contractors and their dependants at a military posting overseas, including the British overseas territories, the Channel Islands and the Isle of Man, under the vaccination scheme provided or approved by the UK Defence Medical Services.

[F53“vaccine certificate” means a certificate in English, French or Spanish issued by the competent health authority of a relevant country [F54, other than a European country listed in the table in paragraph 11 or the United States of America,] which contains—

(a)

P’s full name;

(b)

P’s date of birth;

(c)

the name and manufacturer of the vaccine that P received;

(d)

the date that P received each dose of the vaccine;

(e)

details of either the identity of the issuer of the certificate or the country of vaccination, or both.]

Textual Amendments

F41A copy may be downloaded from https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_11Nov2021.pdf. A hard copy may be obtained from the Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU

[F5510A.  The following countries and territories are approved third countries or territories for the purposes of this Schedule—N.I.

Textual Amendments

10B.  The table referred to in the definition of “North American Certificate” in paragraph 10 is—N.I.

State, District or ProvenceCertificate Name
New YorkExcelsior Pass Plus
CaliforniaDigital COVID-19 Vaccine Record
Washington StateWA Verify]

Textual Amendments

11.  The table referred to in [F56paragraph 10] [F57except in the definition of “North American Certificate”] follows—N.I.

Relevant countryRelevant regulator
a member StateEuropean Medicines Agency
AndorraEuropean Medicines Agency
[F58Australia The Therapeutic Goods Administration]
[F58CanadaHealth Canada]
IcelandEuropean Medicines Agency
LichtensteinEuropean Medicines Agency
MonacoEuropean Medicines Agency
NorwayEuropean Medicines Agency
San MarinoEuropean Medicines Agency
SwitzerlandSwissmedic
the United States of AmericaUnited States Food and Drug Administration
Vatican City StateEuropean Medicines Agency

Textual Amendments

[F5912.  The countries and territories referred to in the definitions of “authorised vaccine” and “relevant country” [F60in paragraph 10] are—N.I.

[F61Albania]

[F62Angola]

[F62Anguilla]

Antigua and Barbuda

[F62Argentina]

[F62Armenia]

[F62Azerbaijan]

[F61Bahamas]

Bahrain

[F61Bangladesh]

Barbados

[F63Belarus]

[F62Belize]

[F62Bermuda]

[F63Bolivia]

[F61Bosnia and Herzegovina]

[F62Botswana]

[F61Brazil]

[F63British Antarctic Territory]

[F63British Indian Ocean Territory]

[F63British Virgin Islands]

Brunei

[F62Cambodia]

[F62Cayman Islands]

[F61Chile]

[F61Colombia]

[F62Costa Rica]

[F63Democratic Republic of Congo]

[F62Djibouti ]

Dominica

[F63Dominican Republic]

[F63Ecuador]

[F61Egypt]

[F62Eswatini]

[F63Falkland Islands]

[F61Georgia]

[F61Ghana]

[F62Gibraltar]

[F61Grenada]

[F63Guernsey]

[F62Guyana]

[F62Honduras]

[F61Hong Kong]

[F61India]

[F61Indonesia]

[F63Isle of Man]

Israel

[F61Jamaica]

Japan

[F63Jersey]

[F61Jordan]

[F61Kenya]

[F61Kosovo]

Kuwait

[F63Laos]

[F62Lebanon]

[F62Lesotho]

[F63Libya]

[F62Madagascar]

[F63Malawi]

Malaysia

[F61Maldives]

[F62Mauritius]

[F61Moldova]

[F62Mongolia]

[F61Montenegro]

[F63Montserrat]

[F61Morocco]

[F63Mozambique]

[F61Namibia]

[F62Nepal]

New Zealand

[F61Nigeria]

[F61North Macedonia]

[F62Occupied Palestinian Territories]

[F61Oman]

[F61Pakistan]

[F62Panama]

[F62Peru]

[F61the Philippines]

[F63Pitcairn, Henderson, Ducie and Oeno Islands]

Qatar

[F62Rwanda]

[F63Samoa]

Saudi Arabia

[F63Senegal]

[F61Serbia]

[F62Seychelles]

[F62Sierra Leone]

Singapore

[F61South Africa]

[F63South Georgia and the South Sandwich Islands]

[F63the Soverign Base Areas of Akrotiri and Dhekelia in the Island of Cyprus]

South Korea

[F62Sri Lanka]

[F63St Helena, Ascension and Tristan da Cunha]

[F62Suriname]

[F61St Kitts and Nevis]

[F61St Lucia]

[F61St Vincent and the Grenadines]

Taiwan

[F62Tanzania]

[F61Thailand]

[F62Trinidad and Tobago]

[F62Tunisia]

[F61Turkey]

[F63Turks and Caicos Islands]

[F62Uganda]

[F61Ukraine]

United Arab Emirates

[F62Uruguay]

[F63Vanuatu]

[F61Vietnam]

[F63Zambia]

[F63Zimbabwe]]

Textual Amendments

[F6413.—(1) In the definition of “authorised vaccine” in paragraph 10, the reference to doses received in a relevant country listed in paragraph 12 includes doses administered to a person, otherwise than in a relevant country, by a person acting on behalf of the United Nations and authorised to administer the vaccination in that capacity.N.I.

(2) Where a course of doses of an authorised vaccine has been administered to a person, otherwise than in a relevant country, by a person acting on behalf of the United Nations and authorised to administer the vaccination in that capacity—

(a)the person to whom the doses have been administered is to be treated for the purposes of paragraph 2 as having received those doses in a relevant country listed in paragraph 12, and

(b)the reference in the definition of “vaccine certificate” in paragraph 10 to the competent health authority of a relevant country is to be construed as including the person acting on behalf of the United Nations.]]

Textual Amendments